Company type | Limited liability company |
---|---|
Industry | Pharmaceutical Health care and diagnostics[1] |
Founded | 1886 in Naples |
Founder | Archimede Menarini |
Headquarters | , Italy |
Area served | Worldwide |
Key people |
|
Revenue | € 3,8 billion[5] |
Number of employees | 17,650 (2020)[5] |
Parent | Unilab Group |
Website | https://www.menarini.com/ |
The Menarini Group is an Italian pharmaceutical company. Its headquarters is in Florence, Tuscany, and it has three divisions: Menarini Ricerche, Menarini Biotech, and Menarini Diagnostics. It develops pharmacological solutions for cardiovascular diseases, oncology, pain/inflammation, asthma and anti-infectives. Menarini's research activities are carried out through Menarini Ricerche, which deals with all R&D activities, from the creation of new projects to drug registration. Its Menarini Biotech follows the creation of a biotechnological drug from the very early stages of research, through to the pilot scale and up to industrial production. The Group's Menarini Diagnostics division is a healthcare company with a worldwide network of affiliates partners and distributors focused on diabetes, haematology, clinical chemistry, urinalysis, and immunology. In 2020, the company had 17,650 employees worldwide.[6]
Massimiliana Landini Aleotti and her three children inherited the company, valued at US$11.6 billion, following the death of her husband in May 2014.[7]
Menarini developed a rapid COVID-19 test amid the COVID-19 pandemic in Italy, capable of giving a result in just 20 minutes.[8]